After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
© 2023 LBNN - All rights reserved.